Cenersen
Cenersen (EL625) is an oligonucleotide targeting TP53. Cenersen can eliminate the activity of TP53 gain-of-function mutants and increase the sensitivity of lymphoma cells to cytotoxic chemotherapy in vitro. Cenersen can be used for the study of chronic lymphocytic leukemia (CLL) [1].
Product Specifications
Product Name Alternative
EL625
UNSPSC
12352211
Target
MDM-2/p53
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
95.07
Smiles
[Cenersen]
References & Citations
[1]Lanasa MC, et al. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Feb;53 (2) :218-24.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-171499/Cenersen-SDS-MedChemExpress.pdf
Scientific Category
Oligonucleotides
Clinical Information
Phase 2
CAS Number
[872847-66-0]
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
